Literature DB >> 16339113

LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice.

Kyriakos E Kypreos1, Vassilis I Zannis.   

Abstract

We have used adenovirus-mediated gene transfer and bolus injection of purified apolipoprotein E (apoE) in mice to determine the contribution of LDL receptor family members in the clearance of apoE-containing lipoproteins in vivo and the factors that trigger hypertriglyceridemia. A low dose [5 x 10(8) plaque-forming units (pfu)] of an adenovirus expressing apoE4 did not normalize plasma cholesterol levels of apolipoprotein E-deficient (apoE(-/-)) x low density lipoprotein receptor-deficient (LDLr(-/-)) mice and induced hypertriglyceridemia. A similar phenotype of combined dyslipidemia was induced in apoE(-/-) or apoE(-/-) x LDLr(-/-) mice after infection with a low dose (4 x 10(8) pfu) of an adenovirus expressing the apoE4[R142V/R145V] mutant previously shown to be defective in receptor binding. In contrast, a low dose of 5 x 10(8) pfu of the apoE4-expressing adenovirus corrected hypercholesterolemia in apoE(-/-) mice and did not trigger hypertriglyceridemia. Bolus injection of purified apoE in apoE(-/-) x LDLr(-/-) mice did not clear plasma cholesterol levels and induced mild hypertriglyceridemia. In contrast, similar injection of apoE in apoE(-/-) mice cleared plasma cholesterol and caused transiently mild hypertriglyceridemia. These findings suggest that a) the LDL receptor alone can account for the clearance of apoE-containing lipoproteins in mice, and the contribution of other receptors is minimal, and b) defects in either the LDL receptor or in apoE that affect its interactions with the LDL receptor, increase the sensitivity to apoE-induced hypertriglyceridemia in mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339113     DOI: 10.1194/jlr.M500322-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  17 in total

1.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

2.  Domains of apoE4 required for the biogenesis of apoE-containing HDL.

Authors:  Alexander M Vezeridis; Angeliki Chroni; Vassilis I Zannis
Journal:  Ann Med       Date:  2011-06       Impact factor: 4.709

3.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

4.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

5.  Tissue Uptake Mechanisms Involved in the Clearance of Non-Protein Nanoparticles that Mimic LDL Composition: A Study with Knockout and Transgenic Mice.

Authors:  Elaine N Daminelli; Panagiotis Fotakis; Carlos H Mesquita; Raul C Maranhão; Vassilis I Zannis
Journal:  Lipids       Date:  2017-11-01       Impact factor: 1.880

6.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

7.  Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis; Efstratios Stratikos
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

8.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

9.  Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein.

Authors:  Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochemistry       Date:  2007-07-27       Impact factor: 3.162

10.  Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

Authors:  D Sanoudou; A Duka; K Drosatos; K C Hayes; V I Zannis
Journal:  Pharmacogenomics J       Date:  2009-12-01       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.